Medicine and Dentistry
Patient
100%
Therapeutic Procedure
53%
Combination Therapy
34%
Inpatient
32%
Malignant Neoplasm
26%
Neoplasm
23%
Non Small Cell Lung Cancer
23%
Disease
22%
Oncology
18%
Clear Cell Renal Cell Carcinoma
16%
Gastrointestinal Stromal Tumor
16%
Overall Survival
15%
Lung Cancer
13%
Chemotherapy
12%
Analysis
12%
Survival
11%
Biological Marker
10%
Surgery
10%
Immunotherapy
10%
Toxicity
10%
Nivolumab
9%
Progression Free Survival
9%
Transitional Cell Carcinoma
9%
Imatinib
8%
Systemic Therapy
7%
Soft Tissue Sarcoma
7%
Diagnosis
7%
Cisplatin
7%
Clinical Trial
7%
Radiation Therapy
7%
Follow up
7%
Age
7%
Prostate Cancer
6%
Bladder Cancer
6%
Targeted Therapy
6%
Nodular Melanoma
6%
Arm
6%
Cells
6%
Pembrolizumab
6%
Sunitinib
5%
Adverse Event
5%
Evaluation Study
5%
Older Adult
5%
Cancer
5%
Recurrent Disease
5%
Metastatic Carcinoma
5%
Carboplatin
5%
Neoadjuvant Chemotherapy
5%
Muscle Invasive Bladder Cancer
5%
Platinum
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
24%
Chemotherapy
21%
Neoplasm
16%
Malignant Neoplasm
14%
Diseases
14%
Overall Survival
13%
Nivolumab
13%
Toxicity
12%
Cisplatin
12%
Gastrointestinal Stromal Tumor
10%
Immunotherapy
10%
Progression Free Survival
10%
Survival
9%
Renal Cell Carcinoma
8%
Imatinib
8%
Gemcitabine
7%
Pembrolizumab
7%
Carboplatin
7%
Platinum
7%
Transitional Cell Carcinoma
6%
Paclitaxel
6%
Adverse Event
6%
Lung Cancer
6%
Ipilimumab
6%
Solid Malignant Neoplasm
6%
Sunitinib
6%